20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Reata Pharmaceuticals Inc (NASDAQ:RETA) reported the FDA approval of SKYCLARYS for patients with Friedreich's ataxia.
With this approval, the FDA granted a rare pediatric disease priority review voucher.
Reata Pharmaceuticals shares jumped 175% to $85.75 in pre-market trading.
These analysts made changes to their price targets on Reata Pharmaceuticals following the release of results.
- Barclays raised the price target on Reata Pharmaceuticals from $50 to $90. Barclays analyst Carter Gould maintained an Overweight rating.
- Goldman Sachs boosted the price target on Reata Pharmaceuticals from $117 to $185. Goldman Sachs analyst Madhu Kumar maintained a Buy rating.
- Citigroup increased the price target on Reata Pharmaceuticals from $53 to $120. Citigroup analyst Yigal Nochomovitz maintained a Buy rating.
Read More: $1M Bet On Glatfelter? Check Out These 4 Penny Stocks Insiders Are Buying
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!